logo

For the Inventor, By the Inventor

Bengaluru, India

Seetharaman Manojveer

This inventor holds 6 USPTO granted patents and 6 published patent applications. Top assignee: Sudo Biosciences Limited. Active years: 2023-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Seetharaman Manojveer. Retrieved from https://idiyas.com/inventor/seetharaman-manojveer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 83.3

Average Co-Inventor Count = 6.6

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:

goldMedal6 out of 6 
 
Sudo Biosciences Limited
 patents

Years Active: 2023-2026

Loading Chart...
6 patents (USPTO):Explore Patents
1. 12668594 - TYK2 inhibitors and uses thereof (2026-06-30),
2. 12600721 - TYK2 inhibitors and uses thereof (2026-04-14),
3. 12122785 - Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors (2024-10-22),
4. 12103937 - Substituted pyridines and pyridazines as TYK2 inhibitors (2024-10-01),
5. 12084458 - Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors (2024-09-10),
6. 11613548 - Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors (2023-03-28),

Title: Seetharaman Manojveer: Innovator in TYK2 Inhibitors

Introduction

Seetharaman Manojveer is a prominent inventor based in Bengaluru, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of TYK2 inhibitors. With a total of 6 patents to his name, his work is paving the way for advancements in medical treatments.

Latest Patents

Seetharaman's latest patents include innovative compounds that serve as TYK2 inhibitors. One of his notable patents describes substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as effective TYK2 inhibitors. This patent outlines methods for creating these compounds, as well as pharmaceutical compositions and medicaments that incorporate them. These compounds are intended for use in treating various conditions, diseases, or disorders that could benefit from the modulation of TYK2 activity. Another patent focuses on substituted pyridines and pyridazines, detailing similar methods and applications in the treatment of relevant medical conditions.

Career Highlights

Seetharaman is currently employed at Sudo Biosciences Limited, where he continues to innovate and develop new pharmaceutical solutions. His expertise in the field has positioned him as a key player in the research and development of TYK2 inhibitors.

Collaborations

Seetharaman collaborates with talented individuals in his field, including coworkers Anjali Pandey and Gregory Dietsch. Their combined efforts contribute to the advancement of research and the development of new therapeutic options.

Conclusion

Seetharaman Manojveer's work in the field of TYK2 inhibitors showcases his dedication to innovation and medical advancement. His contributions are significant in the ongoing quest for effective treatments for various diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…